COVID-19 - September 9, 2020
Pfizer and BioNTech to potentially supply EU with 200 million vaccine doses
Pfizer and BioNTech have had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate against SARS-CoV-2 to European Union (EU) Member States, with an option for further 100 million doses. Deliveries would be starting by the end of 2020, subject to clinical […]
COVID-19 - September 9, 2020
AstraZeneca vaccine trial paused after participant falls ill
The Phase III clinical trials for a coronavirus vaccine, developed by AstraZeneca and Oxford University, have been paused after a participant had an adverse reaction in the UK. As part of the ongoing randomized, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the pause […]
COVID-19 - September 8, 2020
Pharma giants sign COVID-19 vaccine safety pledge
Nine leading US and European vaccine developers have signed a pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. The CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck (known as MSD outside the United States and Canada), Moderna, Novavax, Pfizer and […]
COVID-19 - September 8, 2020
Hyperinflammatory syndrome in children with COVID-19 described
Researchers at Karolinska Institutet and Science for Life Laboratory in Sweden and Tor Vergata University of Rome in Italy have mapped the immune response in children affected by a rare but life-threatening inflammatory syndrome associated with COVID-19. The study, which is published in the scientific journal Cell, reveals that the inflammatory response differs from that […]
COVID-19 - September 7, 2020
Swedish researchers have identified nanobodies that may prevent COVID-19 infection
Researchers at Karolinska Institutet have identified a small neutralizing antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells. The researchers believe this nanobody has the potential to be developed as an antiviral treatment against COVID-19. The results are published in the journal Nature Communications. “We hope our findings can […]
COVID-19 - September 5, 2020
Titers of antibodies do not decline within 4 months according to Icelandic study
Scientists at deCODE genetics in Iceland, a subsidiary of Amgen, and their collaborators, have published a study in The New England Journal of Medicine, that shows that antiviral antibodies against SARS-CoV2 do not decline within four months of diagnosis. The aim of the study was to obtain understanding of the nature and durability of the […]
